Literature DB >> 6246299

Cytotoxicity on tumor cells of peripheral blood monocytes and tumor-associated macrophages in patients with ascites ovarian tumors.

A Mantovani, N Polentarutti, G Peri, Z B Shavit, A Vecchi, G Bolis, C Mangioni.   

Abstract

Mononuclear phagocytes were isolated from the peripheral blood (PB) and ascites tumors of 35 patients with epithelial ovarian tumors. After 48 hours of incubation with the TU5 tumor, tumor-associated macrophages (TAM) and PB monocytes from cancer patients showed lower cytolytic activity than did control cells, but by 72 hours there was little difference between control and ovarian cancer effector cells. Primary ovarian carcinoma cultures were heterogeneous in their susceptibility to macrophage cytotoxicity. Tumor cells from 7 patients were significantly lysed by monocytes and macrophages, whereas four ovarian cancer cell preparations were resistant to cytotoxicity. A "feeding" effect of mononuclear phagocytes on non-lysable tumor cells was detected in terms of both lower [3H]thymidine-release values in the cytolysis assay and increased proliferation in cytostasis assays. Thus patients with ovarian carcinomatous ascites PB monocytes and TAM had impaired cytotoxicity against a tumor cell line, and primary ovarian carcinoma cultures were heterogeneous in their interaction with mononuclear phagocytes.

Entities:  

Mesh:

Year:  1980        PMID: 6246299     DOI: 10.1093/jnci/64.6.1307

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  17 in total

1.  Cancer chemotherapeutics as immunomodulators.

Authors:  F Spreafico; A Vecchi; F Colotta; A Montovani
Journal:  Springer Semin Immunopathol       Date:  1985

2.  Autologous tumor killing and natural cytotoxic activity of tumor-associated macrophages in cancer patients.

Authors:  E Yanagawa; A Uchida; M Moore; M Micksche
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

3.  The in vitro development of cytotoxicity in response to granulocyte/macrophage-colony-stimulating factor or interferon gamma in the peripheral blood monocytes of patients with solid tumors: modulation by arachidonic acid metabolic inhibitors.

Authors:  D P Braun; K P Siziopikou; L C Casey; J E Harris
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Decreased monocyte-mediated cytostasis of human cancer cell in patients with lung cancer.

Authors:  Y Nakata; J Yamashita; T Kishi; M Kataoka; T Ejiri; T Ohnoshi; I Kimura
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

5.  Chemiluminescence, suppression and cytotoxicity in peripheral blood mononuclear cells from solid tumor cancer patients.

Authors:  D P Braun; K P De Boer; J E Harris
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

6.  Inhibition of lymphocyte mitogenesis by factor(s) released from macrophages isolated from ascitic fluid of advanced ovarian cancer patients.

Authors:  B Sheid; J Boyce
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

7.  Tumoricidal effect of human macrophage-colony-stimulating factor against human-ovarian-carcinoma-bearing athymic mice and its therapeutic effect when combined with cisplatin.

Authors:  T Adachi; H Mano; Y Shinohara; T Nakanishi; T Suzuki; K Ino; N Kato; T Okamoto; A Nawa; S Goto
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

8.  Natural cytotoxicity of lymphocytes and monocytes and its augmentation by OK432 in melanoma patients.

Authors:  E Yanagawa; A Uchida; E M Kokoschka; M Micksche
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

9.  Antitumour potential of pleural cavity macrophages in lung cancer patients without malignant effusion.

Authors:  S Kimura; S Sone; K Takahashi; T Uyama; T Ogura; Y Monden
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

10.  Cellular immune function study in an ovarian cancer-prone kindred.

Authors:  G S Schuelke; H T Lynch; J F Lynch; E A Chaperon; J A Recabaren; B Grabner; W A Albano
Journal:  Br J Cancer       Date:  1982-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.